Copyright
©The Author(s) 2020.
World J Clin Cases. Oct 26, 2020; 8(20): 4793-4806
Published online Oct 26, 2020. doi: 10.12998/wjcc.v8.i20.4793
Published online Oct 26, 2020. doi: 10.12998/wjcc.v8.i20.4793
Figure 1 Summary findings of one-way sensitivity analyses for Sweden.
A: One-way sensitivity analyses in midgut neuroendocrine tumors; B: One-way sensitivity analyses in pancreatic neuroendocrine tumors. QALY: Quality-adjusted life year; PPS: Post-progression survival; PFS: Progression-free survival; GI-NETs: Gastrointestinal-neuroendocrine tumors; LAR: Long-acting release; CT: Computed tomography; MRI: Magnetic resonance imaging; P-NET: Pancreatic-neuroendocrine tumor; AE: Adverse event.
Figure 2 Summary findings of one-way sensitivity analyses for Norway.
A: One-way sensitivity analyses in midgut neuroendocrine tumors; B: One-way sensitivity analyses in pancreatic neuroendocrine tumors. QALY: Quality-adjusted life year; PPS: Post-progression survival; PFS: Progression-free survival; GI-NETs: Gastrointestinal-neuroendocrine tumors; LAR: Long-acting release; CT: Computed tomography; MRI: Magnetic resonance imaging; P-NET: Pancreatic-neuroendocrine tumor; AE: Adverse event.
- Citation: Palmer J, Leeuwenkamp OR. Cost-effectiveness of lutetium (177Lu) oxodotreotide vs everolimus in gastroenteropancreatic neuroendocrine tumors in Norway and Sweden. World J Clin Cases 2020; 8(20): 4793-4806
- URL: https://www.wjgnet.com/2307-8960/full/v8/i20/4793.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v8.i20.4793